Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Galderma's Announcement Regarding NEMLUVIO (FDA Approval for the Treatment of Moderate to Severe Atopic Dermatitis)

TOKYO, December 16, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on December 14 that the U.S. Food and Drug Administration (FDA) has approved the humanized anti-human IL-31 receptor A monoclonal antibody NEMLUVIO® (nemolizumab) for the treatment of moderate to severe atopic dermatitis. NEMLUVIO was created by Chugai, and its clinical development outside Japan is being conducted by Galderma.

Please refer to the link below for details of the Galderma's press release:
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-patients-moderate-severe-atopic

###

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324 Japan
Media Relations Group TEL:+81-(0)3-3273-0881 E-mail:pr@chugai-pharm.co.jp
Investor Relations Group TEL:+81-(0)3-3273-0554 E-mail:ir@chugai-pharm.co.jp